133 related articles for article (PubMed ID: 21374569)
21. On the design of in situ forming biodegradable parenteral depot systems based on insulin loaded dialkylaminoalkyl-amine-poly(vinyl alcohol)-g-poly(lactide-co-glycolide) nanoparticles.
Packhaeuser CB; Kissel T
J Control Release; 2007 Nov; 123(2):131-40. PubMed ID: 17854938
[TBL] [Abstract][Full Text] [Related]
22. Improving release completeness from PLGA-based implants for the acid-labile model protein ovalbumin.
Duque L; Körber M; Bodmeier R
Int J Pharm; 2018 Mar; 538(1-2):139-146. PubMed ID: 29355654
[TBL] [Abstract][Full Text] [Related]
23. Influence of end groups on in vitro release and biological activity of lysozyme from a phase-sensitive smart polymer-based in situ gel forming controlled release drug delivery system.
Chhabra S; Sachdeva V; Singh S
Int J Pharm; 2007 Sep; 342(1-2):72-7. PubMed ID: 17560056
[TBL] [Abstract][Full Text] [Related]
24. Continuous Preparation of 1:1 Haloperidol-Maleic Acid Salt by a Novel Solvent-Free Method Using a Twin Screw Melt Extruder.
Lee HL; Vasoya JM; Cirqueira ML; Yeh KL; Lee T; Serajuddin AT
Mol Pharm; 2017 Apr; 14(4):1278-1291. PubMed ID: 28245127
[TBL] [Abstract][Full Text] [Related]
25. Controlled release formulations of risperidone antipsychotic drug in novel aliphatic polyester carriers: Data analysis and modelling.
Siafaka PI; Barmpalexis P; Lazaridou M; Papageorgiou GZ; Koutris E; Karavas E; Kostoglou M; Bikiaris DN
Eur J Pharm Biopharm; 2015 Aug; 94():473-84. PubMed ID: 26159838
[TBL] [Abstract][Full Text] [Related]
26. Limonene GP1/PG organogel as a vehicle in transdermal delivery of haloperidol.
Lim PF; Liu XY; Kang L; Ho PC; Chan YW; Chan SY
Int J Pharm; 2006 Mar; 311(1-2):157-64. PubMed ID: 16451823
[TBL] [Abstract][Full Text] [Related]
27. A facile way to fabricate polyester microcapsules.
Yu X; Zhu J
J Control Release; 2011 Nov; 152 Suppl 1():e128-9. PubMed ID: 22195798
[No Abstract] [Full Text] [Related]
28. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
Desai KG; Mallery SR; Schwendeman SP
Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
[TBL] [Abstract][Full Text] [Related]
29. Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb Pro: formulation aspects and nanoparticle stability to nebulization.
Beck-Broichsitter M; Kleimann P; Gessler T; Seeger W; Kissel T; Schmehl T
Int J Pharm; 2012 Jan; 422(1-2):398-408. PubMed ID: 22001839
[TBL] [Abstract][Full Text] [Related]
30. Production of insulin-loaded poly(ethylene glycol)/poly(l-lactide) (PEG/PLA) nanoparticles by gas antisolvent techniques.
Elvassore N; Bertucco A; Caliceti P
J Pharm Sci; 2001 Oct; 90(10):1628-36. PubMed ID: 11745721
[TBL] [Abstract][Full Text] [Related]
31. Novel cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: a suitability study.
Mondon K; Zeisser-Labouèbe M; Gurny R; Möller M
Eur J Pharm Biopharm; 2011 Jan; 77(1):56-65. PubMed ID: 20888909
[TBL] [Abstract][Full Text] [Related]
32. Protein bioactivity and polymer orientation is affected by stabilizer incorporation for double-walled microspheres.
Kokai LE; Tan H; Jhunjhunwala S; Little SR; Frank JW; Marra KG
J Control Release; 2010 Jan; 141(2):168-76. PubMed ID: 19751780
[TBL] [Abstract][Full Text] [Related]
33. Controlled release matrix tablets of glipizide: Influence of different grades of ethocel and Co-excipient on drug release.
Mehsud SU; Khan GM; Hussain A; Akram M; Akhlaq M; Khan KA; Shakoor A
Pak J Pharm Sci; 2016 May; 29(3):779-87. PubMed ID: 27166548
[TBL] [Abstract][Full Text] [Related]
34. Solubilization of an amphiphilic drug by poly(ethylene oxide)-block-poly(ester) micelles.
Elhasi S; Astaneh R; Lavasanifar A
Eur J Pharm Biopharm; 2007 Mar; 65(3):406-13. PubMed ID: 17291732
[TBL] [Abstract][Full Text] [Related]
35. Solution-mediated phase transformation of salts during dissolution: investigation using haloperidol as a model drug.
Greco K; Mcnamara DP; Bogner R
J Pharm Sci; 2011 Jul; 100(7):2755-68. PubMed ID: 21328581
[TBL] [Abstract][Full Text] [Related]
36. Influences of excipients on in vitro release and in vivo performance of tetanus toxoid loaded polymer particles.
Katare YK; Panda AK
Eur J Pharm Sci; 2006 Jun; 28(3):179-88. PubMed ID: 16517132
[TBL] [Abstract][Full Text] [Related]
37. Influence of selected formulation variables on the preparation of enzyme-entrapped Eudragit S100 microspheres.
Rawat M; Saraf S; Saraf S
AAPS PharmSciTech; 2007 Dec; 8(4):E116. PubMed ID: 18181537
[TBL] [Abstract][Full Text] [Related]
38. Controlled release of hyaluronan oligomers from biodegradable polymeric microparticle carriers.
Hedberg EL; Shih CK; Solchaga LA; Caplan AI; Mikos AG
J Control Release; 2004 Nov; 100(2):257-66. PubMed ID: 15544873
[TBL] [Abstract][Full Text] [Related]
39. Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism.
Wang L; Wang A; Zhao X; Liu X; Wang D; Sun F; Li Y
Int J Pharm; 2012 May; 427(2):284-92. PubMed ID: 22387369
[TBL] [Abstract][Full Text] [Related]
40. Brain Targeting of a Water Insoluble Antipsychotic Drug Haloperidol via the Intranasal Route Using PAMAM Dendrimer.
Katare YK; Daya RP; Sookram Gray C; Luckham RE; Bhandari J; Chauhan AS; Mishra RK
Mol Pharm; 2015 Sep; 12(9):3380-8. PubMed ID: 26226403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
